ASP2453

Networked: 2 relevant articles (1 outcomes, 0 trials/studies)

1.	Nagashima, Takeyuki: 2 articles (01/2022 - 01/2021)
2.	Shimazaki, Masashi: 2 articles (01/2022 - 01/2021)
3.	Homboh, Kazuya: 1 article (01/2022)
4.	Kuramoto, Kazuyuki: 1 article (01/2022)
5.	Mori, Kenichi: 1 article (01/2022)
6.	Nakayama, Ayako: 1 article (01/2022)
7.	Nishizono, Yoshihiro: 1 article (01/2022)
8.	Yuri, Masatoshi: 1 article (01/2022)
9.	Apgar, Joshua F: 1 article (01/2021)
10.	Burke, John M: 1 article (01/2021)

1.	Neoplasms (Cancer) 01/01/2022 - "Here, we characterised the anti-tumour efficacy of ASP2453, a novel KRAS G12C inhibitor, in preclinical models of KRAS G12C-mutated cancer. " 01/01/2022 - "ASP2453 is a potential therapeutic agent for KRAS G12C-mutated cancer. " 01/01/2022 - "We evaluated the in vitro and in vivo activity of ASP2453, alone or in combination with targeted agents and immune checkpoint inhibitors, in KRAS G12C-mutated cancer cells and xenograft models. " 01/01/2021 - "Publicly disclosed clinical data for AMG 510 were used to generate a virtual population, and tumor size changes in response to ASP2453 and AMG 510 were simulated. "
2.	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/01/2021 - "Virtual clinical trial simulations for a novel KRASG12C inhibitor (ASP2453) in non-small cell lung cancer."

1.	Immune Checkpoint Inhibitors
2.	sotorasib